Paul Hastings advised Farmacy Beauty on the deal. Farmacy Beauty announced the sale of the company to Proctor & Gamble. Founded by David Chang, Farmacy Beauty offers “farm-to-face...
You must be a Standard 1 Year member to access this content.
Paul Hastings advised Vance Street Capital Partners on the deal. Vance Street Capital Partners, a Los Angeles-based private equity firm, announced its acquisition of McFarlane Aviation, the leading designer and...
You must be a Standard 1 Year member to access this content.
Paul Hastings advised Vector Capital and its portfolio company, Cheetah Digital on the deal. Willkie Farr & Gallagher advised CM Group. Vector Capital announced the merger between Cheetah...
You must be a Standard 1 Year member to access this content.
Slaughter and May, Khaitan & Co. and Cravath advised Daily Mail and General Trust on the deal. Paul Hastings represented Moody’s Corporation. Daily Mail and General...
You must be a Standard 1 Year member to access this content.
JPMorgan Chase Bank, N.A. and Credit Suisse AG acted as financial advisors to Taboola. JPMorgan Chase Bank, N.A. and Credit Suisse AG are providing committed debt...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Seaport Global Acquisition Corp. on the deal. Seaport Global Acquisition Corp. announced its proposed business combination with Redbox in a transaction that values...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Madison Industries, while Simpson Thacher represented Melrose Industries PLC on the deal. Madison Industries, one of the world’s largest privately held companies,...
You must be a Standard 1 Year member to access this content.
Paul Hastings advised Merck on the deal. Merck, known as MSD outside the United States and Canada, announced a definitive agreement with Alydia Health, a commercial-stage medical...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Xoma Corporation on the deal. Xoma Corporation, a biotechnology and pharmaceutical royalty aggregator announced its multi-license and milestone monetization transaction with Viracta Therapeutics....
You must be a Standard 1 Year member to access this content.
